Actively Recruiting
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Led by EDUARDO ALBENIZ · Updated on 2023-10-24
1200
Participants Needed
15
Research Sites
277 weeks
Total Duration
On this page
Sponsors
E
EDUARDO ALBENIZ
Lead Sponsor
I
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a multicenter, prospective cohort study, which are planned to enroll at least 600 patients who diagnosed the primary gastric cancer (GC); around 50 patients with premalignant gastric lesions (PGLs) and early gastric neoplasias (EGC) treated by endoscopy resection; and no less than 600 healthy normal cohort participants, for more than 18 months in the Spanish population. All participants who enrolled in this registry will be questioned by the life habits survey; and clinical data and biological samples of these participants were analyzed in order to look for new diagnostic tools. The aim of this study is to evaluate clinical, endoscopic and molecular approaches to identify individuals with high-risk of GC. Thus, it would be allow the adoption of preventive measures to reduce mortality through early detection and/or the reduction of its incidence.
CONDITIONS
Official Title
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults over 18 years-old.
- Symptomatic patients undergoing diagnostic gastroscopy for prevalence study of premalignant gastric lesions.
- Patients with premalignant gastric lesions and early gastric cancer indicated for endoscopic resection.
- Patients diagnosed with gastric cancer.
- Controls without gastric pathology or family history of gastric cancer, from EDGAR 1 cohort.
You will not qualify if you...
- Patient refuses to participate in the study.
- Medical, psychological, or legal inability to enter the study.
- For EDGAR 1: previous diagnosis of premalignant gastric lesions, previous gastric surgery, contraindication for gastroscopy or biopsies.
- For EDGAR 2: contraindication for resection or biopsy.
- For EPIGASTRIC: gastric neoplasm other than adenocarcinoma.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Hospital Comarcal de Inca
Palma de Mallorca, Balearic Islands, Spain
Actively Recruiting
2
Hospital de Llevant
Porto Cristo, Balearic Islands, Spain
Actively Recruiting
3
Hospital General de Granollers
Granollers, Barcelona, Spain
Actively Recruiting
4
Consorci Sanitari de Terrassa
Terrassa, Barcelona, Spain
Actively Recruiting
5
Hospital Santos Reyes
Aranda de Duero, Burgos, Spain
Actively Recruiting
6
Hospital de Mérida
Mérida, Extremadura, Spain
Actively Recruiting
7
Hospital Universitario de Ourense
Ourense, Galicia, Spain
Actively Recruiting
8
Hospital Puerta de Hierro
Majadahonda, Madrid, Spain
Actively Recruiting
9
Hospital Universitario de Navarra
Pamplona, Navarre, Spain
Actively Recruiting
10
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Actively Recruiting
11
Hospital Clínic de Barcelona
Barcelona, Spain
Actively Recruiting
12
Hospital Universitario de Burgos
Burgos, Spain
Actively Recruiting
13
Hospital Josep Trueta
Girona, Spain
Actively Recruiting
14
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Spain
Actively Recruiting
15
Hospital Universitario Miguel Servet
Zaragoza, Spain
Actively Recruiting
Research Team
L
Leticia Moreira, MD, PhD
CONTACT
E
Eduardo Albéniz, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here